-Technology for quantitative profiling of protein biomarkers in tissue now available to investigators at DF/HCC member institutions through Brigham
and Women's Pathology Core Facility-
NEW HAVEN, Conn., May 29 /PRNewswire/ -- HistoRx, Inc., announced today that the pathology core facility at Brigham and Women's Hospital (BWH) will begin making the company's AQUA(R) technology for protein biomarker profiling available to the more than 900 Dana-Farber/Harvard Cancer Center (DF/HCC) scientists that are serviced by the facility. Brigham and Women's purchased a HistoRx PM-2000(TM) tissue analysis platform instrument, which incorporates the proprietary AQUA(R) technology, in 2005.
The pathology core facility at BWH is a service hub that provides state-of-the-art tissue-based tests and analysis to investigators at DF/HCC institutions, which include Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, Children's Hospital Boston, Beth Israel Deaconess Hospital, and Massachusetts General Hospital. The core facility is using the AQUA(R) technology to identify and quantify protein biomarkers in tissue samples for researchers advancing studies on cancer diagnostics and drug development. Jon Aster, M.D., Ph.D., core facility director and Associate Professor in the Department of Pathology, and Scott Rodig, M.D., Ph.D., Assistant Professor in Pathology, both of BWH, will oversee the technology access expansion to the DF/HCC member institutions.
The PM-2000(TM) system, now in use at 12 leading cancer and pathology
research centers through the HARP(TM) program (HistoRx Academic Research
Program), enables the reliable measurement of protein biomarkers in tissue
and tissue microarrays based on fluorescent immunohistochemical methods.
Assays developed on the system may be used to better understand the origins
of diseases as well as to aid in patient selection for clinical tri
|SOURCE HistoRx, Inc.|
Copyright©2008 PR Newswire.
All rights reserved